IPO - CytoMed Therapeutics Ltd

Form Type: F-3

Filing Date: 2025-06-13

Corporate Action: Ipo

Type: New

Accession Number: 000164117225015075

Filing Summary: On June 13, 2025, CytoMed Therapeutics Limited filed Form F-3 registration statement with the U.S. SEC to register an offering of securities with an aggregate price not exceeding U.S.$50,000,000. The proposed sale includes ordinary shares, share purchase contracts, share purchase units, warrants, debt securities, and rights units. The registration statement is a part of a shelf registration process which allows the company to offer the securities in one or more offerings over time. Details about specific terms will be provided in supplemental prospectuses. The company is identified as an emerging growth company under federal securities laws. Investors are advised to assess risks involved, as direct ownership pertains to a Singapore holding company conducting business primarily through its subsidiaries in Malaysia. Ordinary Shares of the company are traded under the symbol 'GDTC' on the Nasdaq Capital Market, with a closing price of U.S.$2.02 reported on June 11, 2025. The document emphasizes that selling these securities involves a high degree of risk and investors should consult 'Risk Factors' before investing.